[What should we remember from 2020?]

Jacques-Olivier Bay; Thierry Andre; Carole Bouleuc; Virginie Gandemer; Nicolas Magne; Daniel Orbach; Isabelle Pellier; Nicolas Penel; Manuel Rodrigues; Juliette Thariat; Antoine Thiery-Villemin; Marie Wisley; Gilles L'Allemain; Jacques Robert; Comité de rédaction du Bulletin du cancer

doi:10.1016/j.bulcan.2020.12.002

[What should we remember from 2020?]

Bull Cancer. 2021 Jan;108(1):55-66. doi: 10.1016/j.bulcan.2020.12.002. Epub 2021 Jan 6.

[Article in French]

Authors

Affiliations

¹ CHU de Clermont-Ferrand, service de thérapie cellulaire et d'hématologie clinique adulte, UE7453 CHELTER, Inserm CIC-501, site Estaing, 63000 Clermont-Ferrand, France. Electronic address: jobay@chu-clermontferrand.fr.
² AP-HP, hôpital Saint-Antoine, service d'oncologie médicale, 75012 Paris, France.
³ Sorbonne université, Paris, France; Institut Curie, département de soins de support, 26, rue d'Ulm, 75005 Paris, France.
⁴ CHU de Rennes, service d'hémato-oncologie pédiatrique, 35000 Rennes, France.
⁵ Institut de cancérologie Lucien-Neuwirth, Department of Radiation Oncology, 108 bis, avenue Albert-Raimond, BP 60008, 42270 Saint-Priest-en-Jarez, France; University department of Research and Teaching, Institut de cancérologie Lucien-Neuwirth, 42270 Saint-Priest-en-Jarez, France; Laboratory of Molecular and Cellular Radiobiology, UMR CNRS5822/IN2P3, IPNL, PRISME, 69622 Villeurbanne, France.
⁶ Institut Curie, centre intégré de soins et de recherche en oncologie de l'enfant, adolescent et jeune adulte (SIREDO), 26, rue d'Ulm, 75005 Paris, France.
⁷ Unité immuno-hemato-oncopédiatrie, 49000 Angers, France.
⁸ Lille University, Oscar Lambret Cancer Centre, Medical Oncology Department, 3, rue Frederic-Combemale, 59000 Lille, France.
⁹ PSL Research University, institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
¹⁰ Centre François-Baclesse/ARCHADE, département de radiothérapie, 3, avenue General-Harris, 14000 Caen, France; Laboratoire de physique corpusculaire IN2P3/ENSICAEN - UMR6534, 14000 Caen, France; Normandie University, UNICAEN, 14000 Caen, France.
¹¹ CHRU Jean-Minjoz, department of medical oncology, 25030 Besançon cedex, France; Université de Franche-Comté, UMR1098, SFR IBCT, 25020 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France.
¹² Université de Paris, faculté de médecine, 75000 Paris, France; Centre de recherche des Cordeliers, Team « Inflammation, Complement and Cancer », Inserm, 75000 Paris, France; AP-HP Centre, hôpital Cochin, service de pneumologie, unité d'oncologie thoracique, 75000 Paris, France.
¹³ Institut biologie Valrose, université Côte d'Azur, Inserm U1091, CNRS 7277, 06108 Nice, France.
¹⁴ Université de Bordeaux, Inserm U1218, 33000 Bordeaux, France.

PMID: 33419531
DOI: 10.1016/j.bulcan.2020.12.002

Abstract

The editorial committee of the Bulletin du Cancer is proud to comply with his annual analysis of some of the worldwide updates in oncology that emerge in 2020. We know that all new breakthroughs will not be addressed and apologise for not being comprehensive, but we hope that the topics deciphered herein will bring the reader interesting information in his daily practice in gyneco-oncology, uro-oncology, neuro-oncology, digestive oncology, pneumo-oncology, hemato-oncology, pediatric oncology, or in palliative care.

Keywords: Actualités en cancérologie; Guidelines; New treatments; Nouveaux traitements; Oncology updates; Référentiels.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Brain Neoplasms / therapy
Digestive System Neoplasms / therapy
Female
Genital Neoplasms, Female / therapy
Glioblastoma / therapy
Hematologic Neoplasms / therapy
Humans
Lung Neoplasms / therapy
Male
Medical Oncology*
Neoplasms / therapy*
Neoplasms, Unknown Primary / therapy
Prostatic Neoplasms, Castration-Resistant / genetics
Prostatic Neoplasms, Castration-Resistant / therapy
Urologic Neoplasms / therapy

Substances

Antineoplastic Agents